


Stock Number: 6767



wiltrom
Your Health Partner

Wiltrom Co., Ltd


Presenter: Liang Huang-Chien, Chairman

The background of the slide features a blurred image of a document. On the left side, there is a line graph with a dotted trend line and a solid line. The number '2.5' is visible on the y-axis. A pen is lying diagonally across the document, pointing towards the bottom right.

Safe Harbor Notice

Except for historical information set forth herein, this presentation contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied by such statements. Investors shall assess the potential impact of uncertainties and conduct risk control.

Outline



Company Profile and Business Development

Operational and Financial Overview

Our Journey & Milestones

Building a complete minimally invasive spine surgery platform

- 2009** Spun off from ITRI, a leading research institute with an initial paid-in capital of NT\$18 million.
- 2014** First to secure TFDA & EU approval for our proprietary spinal screws; **Awarded the 11th National Innovation Award**
- 2016** Entered China market with NMPA approval for artificial bone; **Honored with the Taipei Biotech Award and the 24th SME Innovation Research Award.**
- 2018** **First Taiwanese company to enter US & China markets with our own branded spinal products;**
Received the Outstanding Biotechnology Industry Award
- 2019** Launched innovative "Tripod-Fix" system for vertebral fractures with TFDA approval
- 2020** Revenue surpassed NT\$100M; launched new bone cement with TFDA approval; **Awarded the 17th National Innovation Award**
- 2021** **Listed on the Taipei Exchange (TPEX); Tripod-Fix gained EU MDD certification**
- 2022** Revenue broke NT\$200M; opened new in-house manufacturing facility; Tripod-Fix surpassed 1,000 clinical cases
- 2023** Submitted the Tripod-Fix system for EU MDR certification; **Received the Venture Capital Star Award**
- 2024** Secured NT\$270M in private placement from strategic investors; revenue exceeded NT\$300M;
Awarded the 11th Dun & Bradstreet Taiwan SME Elite Award
- 2025** New bone cement achieved national reimbursement in Taiwan; Tripod-Fix entered Brazil & Colombia markets

Product Portfolio & Global Market

Actively Expanding Our Global Footprint

TAM: US\$11.0 Billion


Spinal Fusion



Interbody Fusion System



Bone Graft Substitute




Expanding our spine care portfolio



TAM: US\$1.15 Billion

Vertebral Augmentation System: Tripod-Fix




Bone Cement



1. Growth is propelled by an aging population, a rising incidence of spinal disorders, the increasing adoption of minimally invasive surgery, and advancements in implant materials and surgical techniques.
2. The growing prevalence of conditions like spinal stenosis, degenerative disc disease, and disc herniation—especially in the elderly—is fueling demand for surgical interventions and stabilization solutions.
3. The spinal implant market has grown at a 4.65% CAGR over the past nine years, reaching a projected size of US\$10.96 billion by 2025.

Outline




Company Profile and Business Development
Operational and Financial Overview

Operating Revenue in Recent Years

Steady Revenue Growth

(In Thousands of New Taiwan Dollars)




Year	2018	2019	2020	2021	2022	2023	2024
Operating Revenue Growth Rate	3.0%	25.8%	36.0%	41.2%	43.2%	36.6%	18.5%

Historical Financial Results

2025 Operating Losses Narrow as EU PMCF Expenses Wind Down

(In Thousands of New Taiwan Dollars)

ACCOUNT	2020	2021	2022	2023	2024	Q1~Q3 / 2025
OPERATING REVENUE	102,368	144,499	206,864	282,538	334,730	247,450
GROSS PROFIT	66,000	102,390	156,607	222,598	263,768	194,234
OPERATING EXPENSES	111,868	137,288	166,402	241,001	312,130	202,485
NET OPERATING INCOME(LOSS)	(45,868)	(34,898)	(9,795)	(18,403)	(48,362)	(8,251)
NON-OPERATING INCOME AND EXPENSES	32,563	(12,491)	(7,136)	20,006	(656)	8,838
(INCOME)LOSS FROM CONTINUING OPERATIONS	(13,305)	(47,389)	(16,931)	1,603	(49,018)	587
EARNINGS PER SHARE (NT\$)	(0.51)	(1.64)	(0.58)	0.05	(1.62)	0.02




Consolidated Operating Revenue (by Product Category)

Driven Mainly by Spinal Fusion System Products

(In Thousands of New Taiwan Dollars)

Q1-Q3 / 2025



(1st) Spinal Fusion System

76%

Total Revenue: 187,238 thousand

(2nd) Vertebral Body Augmentation System

19%


Total Revenue: 47,281 thousand

Consolidated Operating Revenue(Regional Contribution)

Deepening Presence in the Taiwan Market and Expanding Across Asia


(In Thousands of New Taiwan Dollars)

Q1-Q3 / 2024



- Taiwan
- Asia
- Central and South America
- Europe and Others
- Service Revenue


Q1-Q3 / 2025



- Taiwan
- Asia
- Central and South America
- Europe and Others
- Service Revenue

Sales Distribution by Market: Taiwan and International 2020 – 2025Q3

(In Thousands of New Taiwan Dollars)





Thank You

wiltrom
Your Health Partner